IQVIA Holdings Inc. 10-Q Summary: Q2 2026
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. IQVIA Holdings Inc. is a leading global provider of clinical research services, commercial insights, and healthcare intelligence. Effective January 1, 2026, the company reorganized its reportable segments from three to two: Commercial Solutions and Research & Development Solutions. The company employs approximately 94,000 people across more than 100 countries.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Revenues | $4,368 | $4,017 | $8,519 | $7,846 |
| Income from Operations | $506 | $506 | $1,020 | $1,002 |
| Net Income (Attributable to IQVIA) | $256 | $266 | $530 | $515 |
| Diluted EPS | $1.53 | $1.54 | $3.14 | $2.94 |
| Operating Cash Flow (YTD) | $1,176 | $1,011 | - | - |
| Total Debt (Principal) | $16,081 | $15,800 | - | - |
| Cash and Equivalents | $1,909 | $2,039 | - | - |
Margins (Q2 2026): Operating margin was 11.6% ($506M / $4,368M). Net income margin was 5.9%.
Material Changes vs. Prior Period
- Revenue Growth: Q2 2026 revenues increased 8.7% ($351M) year-over-year, driven by constant currency growth of 8.5%. Both segments contributed: Commercial Solutions grew 8.6% and Research & Development Solutions grew 8.8%.
- Operating Income: Remained flat at $506M compared to Q2 2025, despite revenue growth, due to increased restructuring costs ($63M vs. $32M) and higher interest expense ($197M vs. $182M).
- Net Income: Decreased 3.8% to $256M in Q2 2026, primarily due to higher interest costs and restructuring expenses offsetting operational gains.
- Debt Restructuring: In June 2026, the company issued €950 million of 4.625% Senior Notes due 2033. Proceeds were used to repay a €550 million Term Loan due 2027 and reduce revolving credit facility borrowings.
- Restructuring: Costs increased significantly to $63M in Q2 2026 (up from $32M in Q2 2025) as the company continues to align resources and reduce overcapacity.
Guidance, Outlook, and Risks
Outlook: Management expects restructuring actions to continue throughout 2026 and into 2027. The company maintains a strong liquidity position with $1,909 million in cash and $1,195 million available under its revolving credit facility. Backlog for Research & Development Solutions increased to $34.2 billion as of June 30, 2026, with approximately $9.2 billion expected to convert to revenue in the next 12 months.
Capital Allocation: On May 7, 2026, the Board increased the stock repurchase authorization by $2,000 million, bringing the total authorized to $15,725 million. The company repurchased $950 million of stock in the first six months of 2026, with $2,819 million remaining authorized.
Risks and Contingencies:
- Tax Regulation: The company is monitoring the impact of the OECD Pillar Two global minimum tax (15%), which became effective in 2025. Top-up taxes were recorded as period costs where applicable.
- Legal: The company is involved in ordinary course legal proceedings; management does not expect a material adverse effect on financial position.
- Market Risk: Approximately 30% of revenues are denominated in foreign currencies, exposing the company to exchange rate fluctuations.
Investor Verification Checklist
- Debt Maturity Profile: Verify the impact of the new €950M 2033 notes on future interest expense and the reduction of short-term debt maturities.
- Restructuring Run-Rate: Confirm the total expected cost of restructuring initiatives extending into 2027 and their impact on future operating margins.
- Segment Recasting: Ensure comparability of historical data by noting the January 1, 2026, segment reorganization (merging Contract Sales & Medical into Commercial Solutions).
- Backlog Conversion: Monitor the conversion rate of the $34.2 billion Research & Development Solutions backlog against revenue recognition timelines.
- Share Repurchase Pace: Track the utilization of the remaining $2.8 billion repurchase authorization against cash flow generation.